Pfizer launches new company focussed on CNS therapies. Credit: Montgomery County Planning Commission/Flickr.

Pfizer has partnered with private investment firm Bain Capital to launch a new company, Cerevel Therapeutics, for the development of new medicines to treat central nervous system (CNS) disorders.

The pharmaceutical giant has announced plans to contribute some of its pre-commercial neuroscience assets to the new company.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cerevel Therapeutics will be gaining Pfizer’s three clinical-stage and multiple pre-clinical compounds targeting various CNS diseases such as Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction.

Bain Capital Private Equity and Bain Capital Life Sciences’ affiliated funds have agreed to support the new company with $350m, and will offer additional capital depending upon requirements in the future.

Bain Capital Private Equity managing director Chris Gordon said: “We are dedicated to developing this promising portfolio of assets thoughtfully, and will provide the right resources to enable Cerevel to build an experienced leadership team that is committed to developing life changing therapies for patients who are struggling with CNS diseases.”

“We will provide the right resources to enable Cerevel to build an experienced leadership team committed to developing life changing therapies for patients with CNS diseases.”

Cerevel Therapeutics will primarily focus on developing drug candidates for therapeutic area with urgent unmet need. It currently has active early development, discovery and research programmes in neuroinflammation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Both Pfizer and Bain Capital will provide support for building a team of CNS scientists and life sciences executives with expertise in clinical development of potential medications for neurological and neuropsychological conditions.

Commenting on the launch, Pfizer said: “Pfizer felt that placing this set of neuroscience assets, after its decision to curtail research within the area, in a company with dedicated focus and expertise in CNS was the optimal next step.”

The company will hold a 25% equity stake in Cerevel. Pfizer Internal Medicine chief scientific officer Morris Birnbaum and Worldwide Business Development senior vice-president Doug Giordano will join Cerevel’s board of directors.